MPNRF honored with Cure MPN Hero award!

Each year for the past three years, Cure Magazine and Incyte Corporation have recognized efforts within the MPN community with their MPN Hero award. The two categories are commitment to the community or individual. Past winners have included Ruben Mesa, Zhenya Senyak, Joyce Niblack, Richard Silver, and many more. We were honored to receive recognition this year for our dedication to serving the MPN community. 

We share this award with all board members and patients who work hard to make a difference for themselves and others living with PV, ET and MF. Click here to read the press release from Cure Magazine.

Nature Medicine: Drug stops reproduction of cancer cells in Myelofibrosis

According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis. Reports John Crispino, PhD, "This new paper shows that Alisertib has an anti-tumor effect in samples of myelofibrosis, similar to what we saw in megakaryocytic leukemia." 
John Crispino is also the Scientific Advisor for the MPN Research Foundation.

Click here to read the original article from Nature, or the press release from Northwestern quoting both Dr. Crispino and Brady Stein.

There is a clinical trial for Alisertib in people with myelofibrosis currently enrolling at Northwestern. Please visit the clinicaltrials.gov listing for this study for further information including how to enroll.